Logotype for Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals (CYCC) investor relations material

Cyclacel Pharmaceuticals Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cyclacel Pharmaceuticals Inc
Q3 2025 earnings summary13 Nov, 2025

Executive summary

  • Shifted focus from biopharmaceuticals to fire safety protection and distribution after acquiring Fitters Sdn. Bhd. in Malaysia on September 12, 2025.

  • Deconsolidated UK subsidiary Cyclacel Limited after its liquidation in January 2025, resulting in a $5.0 million gain.

  • Sold remaining biopharmaceutical asset, plogosertib, in October 2025 for $300,000 plus a potential $170,000 milestone payment.

  • Implemented a one-for-fifteen reverse stock split in July 2025 to meet Nasdaq requirements.

  • Entered into multiple warrant exchange agreements, issuing new shares in exchange for existing warrants.

Financial highlights

  • Net loss for the nine months ended September 30, 2025, was $2.4 million, a significant improvement from $8.2 million loss in the same period last year.

  • Cash and cash equivalents stood at $3.8 million as of September 30, 2025.

  • Product revenue from fire safety equipment sales was $81,000 for Q3 2025.

  • Cost of sales for fire safety equipment was $64,000 for Q3 2025.

  • General and administrative expenses increased to $6.5 million, up 46% year-over-year due to one-time costs from changes in control.

Outlook and guidance

  • Anticipates revenue growth in Q4 2025 following full integration of Fitters Sdn. Bhd.

  • No further material research and development expenditures expected after divestiture of biopharma assets.

  • Substantial doubt exists about ability to continue as a going concern beyond Q1 2026 without additional funding.

  • Current cash resources are expected to fund planned expenditures into Q1 2026.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Cyclacel Pharmaceuticals earnings date

Logotype for Cyclacel Pharmaceuticals Inc
Q4 20256 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Cyclacel Pharmaceuticals earnings date

Logotype for Cyclacel Pharmaceuticals Inc
Q4 20256 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The company's research and development efforts target the regulation of the cell cycle, aiming to treat cancers and other serious diseases that result from abnormal cell division. Cyclacel's pipeline includes small-molecule drugs designed to inhibit specific enzymes and proteins involved in cancer cell growth and survival. The company's therapeutic candidates are being developed for a range of oncology applications, with the goal of addressing unmet medical needs in cancer treatment. The company is headquartered in Berkeley Heights, New Jersey, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage